Product Highlights
 |
Bifurcation |
The Nobori® stent design is well adapted for the treatment of coronary bifurcation disease, one of the most challenging areas in interventional cardiology. |
 |
Patients with Diabetes Mellitus |
Coronary artery disease in diabetics confers an increased mortality risk due to enhanced vessel wall thrombogenicity and more proliferative coronary disease. |
 |
Clinical Trials |
Nobori® stent shows good results |
News
19/12/2011
Nobori Drug Eluting Stent – Now available in a wider
range of sizes!
Terumo receives CE Mark for 2.25 mm and 4.0 mm DES
Now more patients can benefit from this stent known for both its safety and efficacy. Read more about the positive clinical results of Nobori.
29/07/2011
NOBORI JAPAN has been published
in Catheterization Cardiovascular Interventions
This well controlled randomized clinical trial confirmed the hypothesis of non-inferiority of the Nobori Biolimus A9-eluting stent to the Cypher Sirolimus-eluting stent for the primary endpoint of freedom from TVF at 9 months.
17/08/2010
First patient of e-NOBORI has been enrolled
The first patient in e-NOBORI has been enrolled in St. Anne University Hospital, Brno, Czech Republic. e-NOBORI is a prospective, multicentre, observational registry of 8000 patients in Europe, Asia and Latin America. The purpose of e-NOBORI is to further validate safety and efficacy of the Nobori DES System in Real-World Patients.
15/04/2010
NOBORI 2 has been selected for Hot Line 1
Late breaking Registries and Trial Updates at EuroPCR 2010
14/03/2010
NOBORI 2 Female study and NOBORI 2 Bifurcation study
posters were presented at ACC 2010
14/03/2010
NOBORI Japan was presented at ACC 2010
27/01/2010
The Nobori® stent is reimbursed in France
02/10/2009
Nobori® has received the CE mark for 2.75 mm sizes
